The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma
- 1 March 2004
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 40 (4) , 515-520
- https://doi.org/10.1016/j.ejca.2003.09.035
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Surgery of liver metastases from colorectal cancer: new promisesBritish Medical Bulletin, 2002
- Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282Annals of Oncology, 2001
- Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinomaCancer, 1999
- Pancreatic endocrine tumors: Recent advancesAnnals of Oncology, 1999
- Neuroendocrine gastrointestinal tumors - A condensed overview of diagnosis and treatmentAnnals of Oncology, 1999
- Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell CarcinomaNew England Journal of Medicine, 1992
- Karnofsky memorial lecture. An odyssey in the land of small tumors.Journal of Clinical Oncology, 1987
- Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell CarcinomaNew England Journal of Medicine, 1980
- Pancreatic Islet Cell CarcinomaAnnals of Internal Medicine, 1973
- TREATMENT OF MULTIPLE-HORMONE-PRODUCING MALIGNANT ISLET-CELL TUMOUR WITH STREPTOZOTOCINThe Lancet, 1968